Effect of partial retinal destruction and gliosis on the intravitreal pharmacokinetics of HPMPC

Retina

Volumn 15, Issue 6, 1995, Pages 513-517

  Kim, Jung W ^a   El Haig, Wael ^a   Capparelli, Edmund V ^b   Besen, Gilberto ^a   Connor, James D ^c   Freeman, William R ^a  

^a Departments of OphthaImology ^*  (United States)

^b Pharmacology   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gliosis; HPMPC; Intraretinal pharmacokinetics; Intravitreal injection; Laser treatment; Retinal destruction

Indexed keywords

CIDOFOVIR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DIODE LASER; GLIOSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LASER COAGULATION; NONHUMAN; RABBIT; RETINA INJURY; RETINITIS;

ANIMALS; ANTIVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOSINE; GLIOSIS; HALF-LIFE; INJECTIONS; LASER COAGULATION; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; RABBITS; RETINA; VITREOUS BODY;

EID: 0029586087     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/00006982-199515060-00010     Document Type: Article

References (20)

1. Freeman WR. Intraocular antiviral therapy. Arch Ophthalmol 1989;107:1737–1739.
2. Ussery FM, Gibson SR, Conklin RH, et al. Intravitreal ganciclovir in the treatment of AIDS-associated CMV retinitis. Ophthalmology 1988;95:640–648.
3. Cantrill HL, Henry K, Melroe H, et al. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir: long term results. Ophthalmology 1989;96:367–374.
4. Daikos GL, Pulido J, Kathapalia SD, Jackson GG. Intravenous and intraocular ganciclovir for CMV retinitis in patients with AIDS or chemotherapeutic immunosuppression. Br J Ophthalmol 1988;72:521–524.
5. Maurice DM. Use of intravitreal ganciclovir (propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 1987; 103:842–844.
6. Knox K, Drobyski W, Carrigan D. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a bone marrow transplant. Lancet 1991;255:1292–1293.
7. Snoeck R, Sakuma T, De Clercq E, et al. (S)-l-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicro Agents Chemother 1988;32:1839–1844.
8. Huang ES. Human cytomegalovirus. IV. specific inhibition of virus-induced DNA polymerase activity and viral DNA replication by phosphonoacetic acid. J Gen Virol 1975; 16:1560–1565.
9. Neyts J, Snoeck R, Schols D, et al. Selective inhibition of human cytomegalovirus DNA synthesis by (s)-l-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG). Virology 1990;179:41–50.
10. Kern ER, Vogt PE. Comparison of treatment with HPMPC and DHPG on mortality and pathogenesis of murine cytomegalovirus infections. In: Proceedings, 29th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Houston, Texas, Abstract 75 1. Washington, DC: American Society of Microbiology; 1989.
11. Stals FS, De Clercq E, Bruggeman CA. Comparative activity of (s)-l-(3-hydroxy-2-phosphonyl-methoxypropyl) cytosine and 9-(l,3-dihydroxy-2-propoxymethyl) guanine against rat cytomegalovirus infection in vitro and in vivo. Antimicro Agents Chemother 1991;35:2262–2266.
12. De Clercq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidine. Antiviral Res 1987;8:261–272.
13. Dolnak DR, Munguia D, Wiley CA, et al. Lack of retinal toxicity of the anti-CMV drug (S-l-3-hydroxy-2-phosphonyl-methoxypropyl) cytosine (HPMPC). Invest Ophthalmol Vis Sci 1992;33:1557–1563.
14. Flores-Aguilar M, Huang JS, Wiley CA, et al. Long acting therapy of viral retinitis with HPMPC. J Infect Dis 1994; 169:642–647.
15. Kirsch LS, Arevalo JF, Garcia R, et al. A phase II/III study of intravitreal (s)-l-(3-hydroxy-2-phosponylmethoxypropyl) cytosine (HPMPC) for the treatment of CMV retinitis in AIDS patients. Ophthalmology 1995; 102:533–543.
16. Kirsch LS, Arevalo JF, De Clercq E, et al. A phase I/II study of intravitreal cidofovir (HPMPC) for the treatment of cytomegalovirus retinitis in patients with the acquired immune deficiency syndrome. Am J Ophthalmol 1995; 119:466–476.
17. Barza M, Kane A, Baum J. Pharmacokinetics of intravitreal carbenicillin, cefazolin, and gentamicin in Rhesus monkets. Invest Ophthalmol Vis Sci 1983;24:1602–1606.
18. Ficker L, Meredith TA, Gardner S, Wilson LA. Cefazolin levels after intravitreal injection: effect of inflammation and surgery. Invest Ophthalmol Vis Sci 1990; 31:502–505.
19. Connelly MC, Robbins BL, Fridland A. Mechanism of uptake of the phosphonate analog (s)-l-(3-hydroxy-2-phosphonyl-methoxy-propyl) cytosine (HPMPC) in vero cells. Biochem Pharm 1993;46:1053–1057.
20. Freeman WR, Schneiderman TE, Wiley CA, et al. An animal model of focal, subacute viral retinitis. Retina 1993; 13:214–221.